@prefix : <http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl> .
@prefix mp: <http://purl.org/mp/> .
@prefix oa: <http://www.w3.org/ns/oa#> .
@prefix opv: <http://inab.certh.gr/OpenPVSignal> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xml: <http://www.w3.org/XML/1998/namespace> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix time: <http://www.w3.org/2006/time#> .
@prefix openpvsignal: <http://purl.org/OpenPVSignal/OpenPVSignal.owl> .
@base <http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl> .

<http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl> rdf:type owl:Ontology ;
                                                                                       owl:imports <http://purl.org/OpenPVSignal/OpenPVSignal.owl> ,
                                                                                                   mp: ;
                                                                                       rdfs:isDefinedBy "https://apps.who.int/iris/handle/10665/312111"^^xsd:anyURI ;
                                                                                       rdfs:label "Glibenclamide/Glyburide and palpitations in the Asian population"^^rdfs:Literal ;
                                                                                       owl:versionInfo "draft-v0.95-20210819"@en .

#################################################################
#    Annotation properties
#################################################################

###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code
<http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> rdf:type owl:AnnotationProperty .


###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code
<http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> rdf:type owl:AnnotationProperty .


###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code
<http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> rdf:type owl:AnnotationProperty .


###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term
<http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> rdf:type owl:AnnotationProperty .


#################################################################
#    Datatypes
#################################################################

###  http://www.w3.org/2001/XMLSchema#date
xsd:date rdf:type rdfs:Datatype .


#################################################################
#    Object Properties
#################################################################

###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element
<http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> rdf:type owl:ObjectProperty .


###  http://purl.org/mp/references
mp:references rdf:type owl:ObjectProperty .


#################################################################
#    Classes
#################################################################

###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlintroduction
:introduction rdf:type owl:Class .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlsummary
:summary rdf:type owl:Class .


#################################################################
#    Individuals
#################################################################

###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#Introduction
<http://purl.org/OpenPVSignal/OpenPVSignal.owl#Introduction> rdf:type owl:NamedIndividual ,
                                                                      :introduction .


###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#Summary
<http://purl.org/OpenPVSignal/OpenPVSignal.owl#Summary> rdf:type owl:NamedIndividual ,
                                                                 :summary .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlAsianReports24To44Years
:AsianReports24To44Years rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reports_from_asian_countries ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 11 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_max_age> 44 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 24 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                         rdfs:label "Asian reports 24 to 44 years" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlAsianReports45To64Years
:AsianReports45To64Years rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reports_from_asian_countries ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 25 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_max_age> 64 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 45 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                         rdfs:label "Asian reports 45 to 64 years" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlAsianReports65To74Years
:AsianReports65To74Years rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reports_from_asian_countries ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 6 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_max_age> 74 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 65 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                         rdfs:label "Asian reports 65 to 74 years" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlAsianReports6Years
:AsianReports6Years rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reports_from_asian_countries ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 6 ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 0 ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                    rdfs:label "Asian reports 6 years" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlAsianReportsAbove75Years
:AsianReportsAbove75Years rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reports_from_asian_countries ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 5 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 75 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                          rdfs:label "Asian reports above 75 years" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlAsianReportsTotalAbove65Years
:AsianReportsTotalAbove65Years rdf:type owl:NamedIndividual ,
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reports_from_asian_countries ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 11 ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 65 ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                               rdfs:label "Asian reports Total above 65 years" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlAsianReportsTotalBelow64Years
:AsianReportsTotalBelow64Years rdf:type owl:NamedIndividual ,
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reports_from_asian_countries ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 36 ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_max_age> "64.0"^^xsd:float ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                               rdfs:label "Asian reports Total below 64 years" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlAsianTTO0To10Days
:AsianTTO0To10Days rdf:type owl:NamedIndividual ,
                            time:DurationDescription ;
                   time:nominalPosition "days" ;
                   time:numericDuration 10 ;
                   time:numericPosition 0 ;
                   rdfs:label "Asian TTO 0 to 10 days" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlAsianTTO12To28Days
:AsianTTO12To28Days rdf:type owl:NamedIndividual ,
                             time:DurationDescription ;
                    time:nominalPosition "days" ;
                    time:numericDuration 16 ;
                    time:numericPosition 12 ;
                    rdfs:label "Asian TTO 12 to 28 days" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlAsianTTO1To20Years
:AsianTTO1To20Years rdf:type owl:NamedIndividual ,
                             time:DurationDescription ;
                    time:nominalPosition "years" ;
                    time:numericDuration 19 ;
                    time:numericPosition 1 ;
                    rdfs:label "Asian TTO 1 to 20 years" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlAsianTTO33To36Days
:AsianTTO33To36Days rdf:type owl:NamedIndividual ,
                             time:DurationDescription ;
                    time:nominalPosition "days" ;
                    time:numericDuration 3 ;
                    time:numericPosition 33 ;
                    rdfs:label "Asian TTO 33 to 36 days" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlAsianTTO43To61Days
:AsianTTO43To61Days rdf:type owl:NamedIndividual ,
                             time:DurationDescription ;
                    time:nominalPosition "days" ;
                    time:numericDuration 18 ;
                    time:numericPosition 43 ;
                    rdfs:label "Asian TTO 43 to 61 days" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlAsianTTO90To270Days
:AsianTTO90To270Days rdf:type owl:NamedIndividual ,
                              time:DurationDescription ;
                     time:nominalPosition "days" ;
                     time:numericDuration 180 ;
                     time:numericPosition 90 ;
                     rdfs:label "Asian TTO 90 to 270 days" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlAsianTTOWithinAMonth
:AsianTTOWithinAMonth rdf:type owl:NamedIndividual ,
                               time:DurationDescription ;
                      time:nominalPosition "months" ;
                      time:numericDuration 1 ;
                      time:numericPosition 0 ;
                      rdfs:label "Asian TTO Within a month" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlAtrialFibrillation
:AtrialFibrillation rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I4891" ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10003658 ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Atrial fibrillation" ;
                    rdfs:label "Atrial fibrillation" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlChanges_in_activity
:Changes_in_activity rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10008401 ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Changes in physical activity" ;
                     rdfs:label "Changes in activity" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlChanges_in_physical_activity
:Changes_in_physical_activity rdf:type owl:NamedIndividual ,
                                       <http://purl.obolibrary.org/obo/OAE_0001182> ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Changes_in_activity ,
                                                                                                       :Palpitations ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "An ICSR from a non-Asian country reports the case of a 62-year-old woman under therapy with glibenclamide and metformin who developed bouts of palpitations, confusion, and chest discomfort, particularly at times of unpredicted physical activity." ;
                              rdfs:label "Changes in physical activity" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlDefinedDailyDoseNonvmicronized
:DefinedDailyDoseNonvmicronized rdf:type owl:NamedIndividual ,
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :glibenclamide ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :one_day_interval_during_administration ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg" ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 10 ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "10 mg" ;
                                rdfs:label "Defined daily dose nonvmicronized" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlDefinedDailyDoseToMicronized
:DefinedDailyDoseToMicronized rdf:type owl:NamedIndividual ,
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :glibenclamide ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :one_day_interval_during_administration ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg" ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 7 ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "7 mg" ;
                              rdfs:label "Defined daily dose to micronized" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlDiscussion_and_Conclusion
:Discussion_and_Conclusion rdf:type owl:NamedIndividual ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Conclusion> ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Discussion> ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Hypoglycaemia is a sulfonylureas dose-related type A adverse effect. In subjects with preserved autonomic function, the fall in blood glucose levels triggers the adrenergic counter regulation, which manifests through palpitations. Glibenclamide is metabolized by CYP2C9 isoenzyme, which is highly polymorphic. The frequency of polymorphism of defective CYP2C9 alleles (CYP2C9*2 and CYP2C9*3 variants) in South-Asian populations is reported to be 10-25% of a total population; defective isoforms are also present – but much less frequently - in Caucasian populations. Poor metabolizers (CYP2C9*2 and CYP2C9*3 alleles carriers) can show higher plasmatic levels of glibenclamide, leading to low blood glucose levels and triggering counter regulation mechanisms, such as adrenergic response.
Even though observational studies have not shown conclusive results, a literature review supports a relationship between clinical effects and CYP2C9 polymorphic variants. A PK study conducted in Caucasian volunteers saw no clinical effects of the difference in metabolization, but hypoglycaemia was more frequent in one conducted with Chinese volunteers. To date, no regulatory labelling or warning has highlighted the contribution of poor metabolizer status on higher frequency or severity of hypoglycaemia in patients treated with glibenclamide.
Even though ICSRs provide no information on the pharmacogenetic status of patients, short TTO and, to a lesser extent source countries may suggest a pharmacogenetic cause. This can also be a class characteristic.
In this set of VigiBase reports, the proportion of cases with short TTO, and the number of good quality reports coming from Asian countries in relatively young patients might be considered as a signal of the potential association of an increased frequency of palpitations as symptoms of hypoglycaemia in patients treated with glibenclamide who are poor metabolisers. Also, in 32 ICSRs, the sender’s comments highlighted the Asian origin. This hypothesis would need specific pharmacogenetic studies in patients treated with glibenclamide and experiencing hypoglycaemia with short TTO or interacting medications.""" ;
                           rdfs:label "Discussion and Conclusion" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlEnalapril
:Enalapril rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C09AA02" ,
                                                                        "C09BA02" ,
                                                                        "C09BB02" ,
                                                                        "C09BB06" ;
           rdfs:label "Enalapril" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlFurosemide
:Furosemide rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C03CA01" ,
                                                                         "C03CB01" ,
                                                                         "C03EB01" ,
                                                                         "G01AE10" ;
            rdfs:label "Furosemide" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlGefitinib
:Gefitinib rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "L01XE02" ;
           rdfs:label "Gefitinib" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlGlibenclamideDosage10Mg
:GlibenclamideDosage10Mg rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :glibenclamide ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg" ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 10 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "10 mg" ;
                         rdfs:label "Glibenclamide Dosage 10 mg" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlGlibenclamideDosage15Mg
:GlibenclamideDosage15Mg rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :glibenclamide ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg" ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 15 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "15 mg" ;
                         rdfs:label "Glibenclamide Dosage 15 mg" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlGlibenclamideDosage20Mg
:GlibenclamideDosage20Mg rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :glibenclamide ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg" ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 20 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "20 mg" ;
                         rdfs:label "Glibenclamide Dosage 20 mg" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlGlibenclamideDosage2To2.5Mg
:GlibenclamideDosage2To2.5Mg rdf:type owl:NamedIndividual ,
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :glibenclamide ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg" ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 2 ,
                                                                                       2.5 ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "2 mg" ,
                                                                                                  "2.5 mg" ;
                             rdfs:label "Glibenclamide Dosage 2 to 2.5 mg" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlGlibenclamideDosage5Mg
:GlibenclamideDosage5Mg rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :glibenclamide ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg" ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 5 ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "5 mg" ;
                        rdfs:label "Glibenclamide Dosage 5 mg" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlHypoglycemia
:Hypoglycemia rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "E162" ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10020993 ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hypoglycaemia" ;
              rdfs:label "Hypoglycemia" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlIncident_comorbidities_and_incident_concomitant_therapies
:Incident_comorbidities_and_incident_concomitant_therapies rdf:type owl:NamedIndividual ,
                                                                    <http://purl.obolibrary.org/obo/OAE_0001182> ;
                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Palpitations ;
                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Enalapril ,
                                                                                                                                      :Furosemide ,
                                                                                                                                      :IsosorbideDinitrate ,
                                                                                                                                      :Morphine ,
                                                                                                                                      :Nifedipine ;
                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :glibenclamide ;
                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """\"An ICSR from an Asian country reports hypoglycaemia in a 52-year-old woman who was started on dual therapy with metformin 1 g daily and glibenclamide 5 mg; the TTO was 10 days. On day 8, a prescription of 2 g of amoxicillin is reported (only one-day of treatment), and doxycycline 200 mg daily, given for three days, because of an acute upper respiratory infection.
Some anti-infective agents may enhance the hypoglycaemic effect of glibenclamide and infection itself can trigger hypoglycaemia.
An ICSR from a non-Asian country reports hypoglycaemia and palpitations in a 59-year-old woman treated with glibenclamide 5 mg over nine months. Two days before the hypoglycaemic event occurred, the patient had received medication for a cardiac event (morphine, nifedipine, isosorbide dinitrate, furosemide, enalapril).\"""" ;
                                                           rdfs:label "Incident comorbidities and incident concomitant therapies 1" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlIncident_comorbidities_and_incident_concomitant_therapies_2
:Incident_comorbidities_and_incident_concomitant_therapies_2 rdf:type owl:NamedIndividual ,
                                                                      <http://purl.obolibrary.org/obo/OAE_0001182> ;
                                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :AtrialFibrillation ,
                                                                                                                                      :LeftVentricularEjectionFraction ,
                                                                                                                                      :Palpitations ;
                                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "In two reports from a non-Asian country (TTO 170 days and 215 days), palpitations are more likely related with other morbidities (atrial fibrillation, reduced left ventricular ejection fraction). In another ICSR from an Asian country (TTO 270 days), other medications suggesting an acute coronary syndrome are reported." ;
                                                             rdfs:label "Incident comorbidities and incident concomitant therapies 2" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlIsosorbideDinitrate
:IsosorbideDinitrate rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C01DA08" ,
                                                                                  "C01DA58" ,
                                                                                  "C05AE02" ;
                     rdfs:label "Isosorbide Dinitrate" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlLeftVentricularEjectionFraction
:LeftVentricularEjectionFraction rdf:type owl:NamedIndividual ,
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10053222 ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Left ventricular ejection fraction decreased" ;
                                 rdfs:label "Left ventricular ejection fraction decreased" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlLiterature_and_Labelling
:Literature_and_Labelling rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Literature_information> ;
                          mp:references :Ref.11 ,
                                        :Ref.14 ,
                                        :Ref.15 ,
                                        :Ref.16 ,
                                        :Ref.4 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """The US FDA label only mentions CYP2C9 as induced by rifampicin, and potentially reducing glibenclamide plasma levels as a consequence.
There is no mention of poor metabolizers.4 The Health Sciences Authority of Singapore issued a warning about glibenclamide in older patients and renal impairment. However, there is no mention of pharmacogenetic variability.14
A statement from the Royal Dutch Pharmacists Association Working Group concluded that there are no dose recommendations based on patients’ pharmacogenetic status to give at this time (2011).15
“Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement”, an initiative of the South Asian Federation of Endocrine Societies (SAFES), developed in accordance with the American Association of Clinical Endocrinologists/ American College of Endocrinology (AACE/ACE) doesn’t mention pharmacogenetic variability as a cause of sulfonylurea intolerance.11
According to a paper published in 2014, gefitinib product information is the only EMA label containing a warning about CYP2C9 metabolization.16""" ;
                          rdfs:label "Literature and labelling" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlMechanism_of_Glibenclamide
:Mechanism_of_Glibenclamide rdf:type owl:NamedIndividual ,
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Mechanism> ;
                            mp:references :Ref.1 ;
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Glibenclamide is an oral blood glucose lowering drug (BGLD), a second-generation sulfonylurea (SU). SUs induce glucose-independent insulin release from the pancreatic β-cells by binding to the ATP-sensitive potassium (KATP) channel. The polymorphic enzyme cytochrome P450 (CYP) 2C9 is the main enzyme catalysing the biotransformation of SUs." ;
                            rdfs:label "Mechanism of sulfonylyreas" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlMorphine
:Morphine rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A07DA52" ,
                                                                       "N02AA01" ,
                                                                       "N02AA51" ,
                                                                       "N02AG01" ;
          rdfs:label "Morphine" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlNifedipine
:Nifedipine rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C08CA05" ,
                                                                         "C08CA55" ,
                                                                         "C08GA01" ;
            rdfs:label "Nifedipine" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlPalpitations
:Palpitations rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R002" ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10033557 ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Palpitations" ;
              rdfs:label "Palpitations" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlPathophysiology_of_hypoglycaemia
:Pathophysiology_of_hypoglycaemia rdf:type owl:NamedIndividual ,
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hypoglycemia ;
                                  mp:references :Ref.1 ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Hypoglycaemia is a pharmacological, dose-dependent (type A) adverse effect of blood glucose lowering agents, especially insulin and insulin secretagogues. Mild hypoglycaemia is associated with adrenergic and neurogenic symptoms, such as tremor, palpitations and perspiration. Severe hypoglycaemia is characterized by symptoms related to reduced glucose to the brain, such as weakness, poor concentration, slurred speech, confusion or even seizure or coma. In normal individuals, hypoglycaemic counter regulation is a multifactorial process that involves reduction of insulin secretion, increasing glucagon secretion, adrenergic activation, increased growth hormone and cortisol secretion. Hypoglycaemia increases plasma levels of both epinephrine and norepinephrine, released primarily from the adrenal medulla. Recovery from hypoglycaemia is dependent on the adrenergic response. Individuals with preserved autonomic neurological response manifest these higher levels of catecholamines through palpitations, increased heart rate, piloerection, etc.1" ;
                                  rdfs:label "Pathophysiology of hypoglycaemia" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlPharmacodynamicInteraction
:PharmacodynamicInteraction rdf:type owl:NamedIndividual ,
                                     <http://purl.obolibrary.org/obo/OAE_0000121> ;
                            <http://purl.obolibrary.org/obo/RO_0002170> :Hypoglycemia ;
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10013710 ;
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Drug interaction" ;
                            rdfs:label "Pharmacodynamic interaction" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlPolymorphic_CYP2C9
:Polymorphic_CYP2C9 rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> ;
                    mp:references :Ref.12 ,
                                  :Ref.13 ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """The polymorphic CYP2C9 isoenzyme catalyses the biotransformation of SUs in the liver. The mutant alleles CYP2C9*2 and CYP2C9*3 are known to have a reduced drug-metabolizing activity than the wildtype CYP2C9*1, the decrease in catalysing activity of the *3 allele being more pronounced. The
*3 variant is most common in Asians with a frequency of 10%–25% compared to that of 2%– 6% in Caucasians. Involvement of CYP2C19 in the metabolism of SUs is also reported. CYP2C19*2 and CYP2C19*3 are variants that encode a non- functional CYP2C19 enzyme. Individuals with either of the variants are labelled as poor metabolizers.12
In Asian populations, genetic variability of CYP2C9 is dominated by the less functioning allele *3 (3.4% in East Asians and 11.3% in South Asians) while in Europeans, genetic variability expresses mainly the
*2 variant (Europeans 11.7% and admixed Americans 6.6%), Other allelic variants are also present in South Asian and African populations.""" ;
                    rdfs:label "Polymorphic CYP2C9" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlPossible_drug_drug_interactions_2
:Possible_drug_drug_interactions_2 rdf:type owl:NamedIndividual ,
                                            <http://purl.obolibrary.org/obo/OAE_0001182> ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hypoglycemia ;
                                   mp:references :Ref.23 ,
                                                 :Ref.24 ,
                                                 :Ref.25 ,
                                                 :Ref.26 ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Interactions: Several published cases report hypoglycaemia induced by hydroxychloroquine, and observational studies suggest a dose-dependent protective effect of hydroxychloroquine on drug- induced diabetes in rheumatic patients treated with corticosteroids.23-26 Co-administration of anti- infective agents that are CYP2C9 inhibitors can increase the risk of hypoglycaemia in glipizide and glyburide users.26 Therefore, co-administration of other CYP2C9 inhibitors might also increase the risk of hypoglycaemia, although an increased risk of hypoglycaemia might not be present with less strong (non-clinically-relevant) CYP2C9 inhibitors. P-Glycoprotein inhibitors might also increase the risk of hypoglycaemia.26 A few ICSRs of this set mentioned suspected or concomitant drugs that could interact with glibenclamide. It is worth noting that an interacting agent can theoretically exert additive effects on an isoenzyme with genetically reduced functionality." ;
                                   rdfs:label "Possible drug drug interactions 2" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlPossible_interactions
:Possible_interactions rdf:type owl:NamedIndividual ,
                                <http://purl.obolibrary.org/obo/OAE_0001182> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "An ICSR from a non-Asian country reports hypoglycaemia in a 78-year-old woman treated with hydroxychloroquine because of a rheumatoid arthritis. Three Asian country reports mention drugs possibly interacting: one of a 75- year-old woman, who started a triple therapy with metformin 1 g, pioglitazone 30 mg and glibenclamide 5 mg, and presented with palpitations and dizziness on the seventh day; another one mentions phenytoin administration with confusing TTO dates; another report mentions hypoglycaemic symptoms the same day that amoxicillin was administered, and 10 days after the therapy with glibenclamide was started." ;
                       rdfs:label "Possible drug drug interactions 1" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlPrescription_of_glibenclamide
:Prescription_of_glibenclamide rdf:type owl:NamedIndividual ,
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> ;
                               mp:references :Ref.11 ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "According to the National List of Essential Medicines (NLEMs), glibenclamide (2.5 and 5.0 mg) is an essential SU in five countries, India, Pakistan, Nepal, Sri Lanka and Bangladesh. In Sri Lanka, glibenclamide is the most commonly prescribed SU by GPs.11" ;
                               rdfs:label "Prescription of glibenclamide" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlRaquel_Herrera_Comoglio
:Raquel_Herrera_Comoglio rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Author> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_first_name> "Raquel" ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_last_name> "Herrera Comoglio" ;
                         rdfs:label "Raquel Herrera Comoglio" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlRef.1
:Ref.1 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Hoffman RP. Sympathetic mechanisms of hypoglycemic counterregulation. Curr Diabetes Rev. 2007 Aug;3(3):185-93." ;
       rdfs:label "Ref.1" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlRef.10
:Ref.10 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care. 2007 Feb;30(2):389- 94." ;
        rdfs:label "Ref.10" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlRef.11
:Ref.11 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Kalra S, Aamir AH, Raza A, Das AK, Azad Khan AK, Shrestha D, Qureshi MF, Md Fariduddin, Pathan MF, Jawad F, Bhattarai J, Tandon N, Somasundaram N, Katulanda P, Sahay R, Dhungel S, Bajaj S, Chowdhury S, Ghosh S, Madhu SV, Ahmed T, Bulughapitiya U2.Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement. Indian J Endocrinol Metab. 2015 Sep-Oct;19(5):577-96." ;
        rdfs:label "Ref.11" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlRef.12
:Ref.12 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Dawed AY, Zhou K, Pearson ER. Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents. Pharmgenomics Pers Med. 2016 Apr 6;9:17- 29." ;
        rdfs:label "Ref.12" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlRef.13
:Ref.13 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects. Clin Pharmacol Ther. 2017 Oct;102(4):688-700." ;
        rdfs:label "Ref.13" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlRef.14
:Ref.14 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Singapore government, Health Science Authority HSA Recommendations to avoid use of glibenclamide in the elderly and renal- impaired. 31 Dec 2013: http://www.hsa.gov.sg/content/hsa/en/ Health_Products_Regulation/Safety_Informatio n_ and_Product_Recalls/Product_Safety_Alerts/20 13/ recommendations_to.html" ;
        rdfs:label "Ref.14" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlRef.15
:Ref.15 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Annotation of DPWG Guideline for glibenclamide and CYP2C9. https://www.pharmgkb.org/guideline/ PA166104953 Accessed 18 February 2018." ;
        rdfs:label "Ref.15" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlRef.16
:Ref.16 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Ehmann F, Caneva L, Papaluca M. European Medicines Agency initiatives and perspectives on pharmacogenomics. Br J Clin Pharmacol. 2014 Apr;77(4):612-7." ;
        rdfs:label "Ref.16" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlRef.17
:Ref.17 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Kirchheiner J, Brockmöller J, Meineke I, Bauer S, Rohde W, Meisel C, Roots I. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 2002; 71: 286–96." ;
        rdfs:label "Ref.17" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlRef.18
:Ref.18 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Holstein A, Plaschke A, Ptak M, Egberts EH, El- Din J, Brockmöller J, Kirchheiner J Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol. 2005 Jul;60(1):103-6." ;
        rdfs:label "Ref.18" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlRef.19
:Ref.19 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Ragia G, Petridis I, Tavridou A, Christakidis D, Manolopoulos VG.Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics. 2009 Nov;10(11):1781-7." ;
        rdfs:label "Ref.19" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlRef.2
:Ref.2 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Scheen AJ. Drug Interactions of Clinical Importance with Antihyperglycaemic Agents: An Update. Drug Saf. 2005 Jul;28(7):601-631." ;
       rdfs:label "Ref.2" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlRef.20
:Ref.20 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Yin OQ, Tomlinson B, Chow MS. CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. Clin Pharmacol Ther. 2005 Oct;78(4):370-7." ;
        rdfs:label "Ref.20" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlRef.21
:Ref.21 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Holstein A, Hahn M, Patzer O, Seeringer A, Kovacs P, Stingl J. Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia Eur J Clin Pharmacol. 2011 May;67(5):471-6." ;
        rdfs:label "Ref.21" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlRef.22
:Ref.22 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Gökalp O, Gunes A, Cam H, Cure E, Aydın O, Tamer MN, Scordo MG, Dahl ML. Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting. Eur J Clin Pharmacol. 2011 Dec;67(12):1223-9." ;
        rdfs:label "Ref.22" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlRef.23
:Ref.23 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Winter EM, Schrander-van der Meer A, Eustatia-Rutten C, Janssen M. Hydroxychloroquine as a glucose lowering drug. BMJ Case Rep. 2011 Oct 28;2011." ;
        rdfs:label "Ref.23" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlRef.24
:Ref.24 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Shojania K, Koehler BE, Elliott T. Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis. J Rheumatol. 1999 Jan;26(1):195-6." ;
        rdfs:label "Ref.24" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlRef.25
:Ref.25 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Chen YM, Lin CH, Lan TH, Chen HH, Chang SN, Chen YH, Wang JS, Hung WT, Lan JL, Chen DY. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose- dependent manner: a population-based cohort study. Rheumatology (Oxford). 2015 Jul;54(7):1244-9" ;
        rdfs:label "Ref.25" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlRef.26
:Ref.26 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S. Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide. Clin Pharmacol Ther. 2010 Aug;88(2):214-22." ;
        rdfs:label "Ref.26" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlRef.3
:Ref.3 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Thulé PM, Umpierrez G. Sulfonylureas: a new look at old therapy. Curr Diab Rep. 2014 Apr;14(4):473." ;
       rdfs:label "Ref.3" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlRef.4
:Ref.4 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Glyburide FDA label: https://www.accessdata.fda. gov/drugsatfda_docs/label/2009/017532s030l bl.pdf" ;
       rdfs:label "Ref.4" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlRef.5
:Ref.5 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "ATC/DDD Index 2018 2018 https://www.whocc.no/ atc_ddd_index/?code=A10BB01" ;
       rdfs:label "Ref.5" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlRef.6
:Ref.6 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Leonard CE, Han X, Brensinger CM, Bilker WB, Cardillo S, Flory JH, Hennessy S. Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: A retrospective cohort study. Pharmacoepidemiol Drug Saf. 2018 Jan;27(1):9-18." ;
       rdfs:label "Ref.6" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlRef.7
:Ref.7 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Douros A, Yin H, Yu OHY, Filion KB, Azoulay L, Suissa S. Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events. Diabetes Care. 2017 Nov;40(11):1506-1513." ;
       rdfs:label "Ref.7" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlRef.8
:Ref.8 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Zhou M, Wang SV, Leonard CE, Gagne JJ, Fuller C, Hampp C, Archdeacon P, Toh S, Iyer A, Woodworth TS, Cavagnaro E, Panozzo CA, Axtman S, Carnahan RM, Chrischilles EA, Hennessy S. Sentinel Modular Program for Propensity Score-Matched Cohort Analyses: Application to Glyburide, Glipizide, and Serious Hypoglycemia. Epidemiology. 2017 Nov;28(6):838-846." ;
       rdfs:label "Ref.8" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlRef.9
:Ref.9 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Shorr RI, Ray WA, Daugherty JR, Griffin MR. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc. 1996 Jul;44(7):751-5." ;
       rdfs:label "Ref.9" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlReportsFromGermany
:ReportsFromGermany rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsFromNonToAsianCountries ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 4 ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Germany" ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                    rdfs:label "Reports from Germany" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlReportsFromIndia
:ReportsFromIndia rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reports_from_asian_countries ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 8 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/India" ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                  rdfs:label "Reports from India" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlReportsFromJapan
:ReportsFromJapan rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reports_from_asian_countries ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Japan" ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                  rdfs:label "Reports from Japan" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlReportsFromPeru
:ReportsFromPeru rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsFromNonToAsianCountries ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 3 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Peru" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                 rdfs:label "Reports from Peru" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlReportsFromSingapore
:ReportsFromSingapore rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reports_from_asian_countries ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 6 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Singapore" ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                      rdfs:label "Reports from Singapore" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlReportsFromSweden
:ReportsFromSweden rdf:type owl:NamedIndividual ,
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsFromNonToAsianCountries ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Sweden" ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                   rdfs:label "Reports from Sweden" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlReportsFromThailand
:ReportsFromThailand rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reports_from_asian_countries ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 26 ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Thailand" ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                     rdfs:label "Reports from Thailand" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlReportsFromUS
:ReportsFromUS rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsFromNonToAsianCountries ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 29 ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/United_States" ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
               rdfs:label "Reports from US" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlReportsWithAsianTTO0To10Days
:ReportsWithAsianTTO0To10Days rdf:type owl:NamedIndividual ,
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reports_from_asian_countries ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :AsianTTO0To10Days ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 21 ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                              rdfs:label "Reports with Asian TTO 0 to 10 days" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlReportsWithAsianTTO12To28Days
:ReportsWithAsianTTO12To28Days rdf:type owl:NamedIndividual ,
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reports_from_asian_countries ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :AsianTTO12To28Days ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 4 ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                               rdfs:label "Reports with Asian TTO 12 to 28 days" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlReportsWithAsianTTO1To20Years
:ReportsWithAsianTTO1To20Years rdf:type owl:NamedIndividual ,
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reports_from_asian_countries ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :AsianTTO1To20Years ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                               rdfs:label "Reports with Asian TTO 1 to 20 years" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlReportsWithAsianTTO33To36Days
:ReportsWithAsianTTO33To36Days rdf:type owl:NamedIndividual ,
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reports_from_asian_countries ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :AsianTTO33To36Days ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                               rdfs:label "Reports with Asian TTO 33 to 36 days" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlReportsWithAsianTTO43To61Days
:ReportsWithAsianTTO43To61Days rdf:type owl:NamedIndividual ,
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reports_from_asian_countries ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :AsianTTO43To61Days ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                               rdfs:label "Reports with Asian TTO 43 to 61 days" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlReportsWithAsianTTO90To270Days
:ReportsWithAsianTTO90To270Days rdf:type owl:NamedIndividual ,
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reports_from_asian_countries ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :AsianTTO90To270Days ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 4 ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                rdfs:label "Reports with Asian TTO 90 to 270 days" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlReportsWithAsianTTOWithinAMonth
:ReportsWithAsianTTOWithinAMonth rdf:type owl:NamedIndividual ,
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reports_from_asian_countries ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :AsianTTOWithinAMonth ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                 rdfs:label "Reports with Asian TTO Within a month" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlReports_from_Denmark
:Reports_from_Denmark rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsFromNonToAsianCountries ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Denmark" ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                      rdfs:label "Reports from Denmark" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlReports_from_Eritrea
:Reports_from_Eritrea rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsFromNonToAsianCountries ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Eritrea" ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                      rdfs:label "Reports from Eritrea" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlReports_from_Italy
:Reports_from_Italy rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsFromNonToAsianCountries ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Italy" ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                    rdfs:label "Reports from Italy" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlReports_from_Malaysia
:Reports_from_Malaysia rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reports_from_asian_countries ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 3 ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Malaysia" ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                       rdfs:label "Reports from Malaysia" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlReports_from_Namibia
:Reports_from_Namibia rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsFromNonToAsianCountries ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Namibia" ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                      rdfs:label "Reports from Namibia" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlReports_from_Oman
:Reports_from_Oman rdf:type owl:NamedIndividual ,
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsFromNonToAsianCountries ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Oman" ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                   rdfs:label "Reports from Oman" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlReports_from_Spain
:Reports_from_Spain rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsFromNonToAsianCountries ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Spain" ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                    rdfs:label "Reports from Spain" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlReports_from_UK
:Reports_from_UK rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsFromNonToAsianCountries ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/United_Kingdom" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                 rdfs:label "Reports from UK" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlReports_in_Vigibase
:Reports_in_Vigibase rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """A total of 100 Individual Case Safety Reports (ICSRs), with the combination glibenclamide and palpitations were retrieved from VigiBase, the WHO global database of ICSRs, on 15 January 2018, and were reviewed case by case. Four repeated reports were identified, and there was a likely duplicate from the US, therefore only 95 cases were considered. Of these, 47 reports were from Asian countries and 48 reports from non-Asian countries. Most reports included hypoglycaemic symptoms (dizziness, sweating, vision blurred, etc.), and 18 explicitly reported hypoglycaemia. Most of the Asian ICSRs (34/47, 72%) had a completeness score (level of documentation) >0.50. Case series distribution of gender, region and completeness score is set out in Table 1. In Asian ICSRs, the reporter is given in 35 reports (74.5%), and all but one were physicians, the remaining one, a pharmacist. In 32 ICSRs, the sender’s comment highlighted the Asian origin.
Patients were relatively younger in Asia than in the other countries: 36/47 (76.6%) were ≤ 64 years old. The age distribution is described in Table 2.
Onset date and at least start date of glibenclamide therapy were stated in 59 out of 95 ICSRs (57.9%); so it was possible to calculate time-to-onset (TTO) in this subset of reports. In three ICSRs, the onset date was stated as previous to the reported start of drug administration.
In 28 Asian reports, TTO ranged from 0 to 60 days, and in 21 reports, TTO was up to 10 days. In six ICSRs symptoms manifested the same day, and in 11 ICSRs TTO was 1 day. Time to onset is set out in Table 3.
The dose for glibenclamide was reported in 65 cases (68.4%) and ranged from 1.8 mg to 20 mg daily.
Fifty ICSRs reported low doses: one 1.8 mg, 13 cases between 2-2.5 mg, 33 a dose of 5 mg, two with 3.5 mg and one with 7.5 mg. Nine patients were treated with 10 mg, three with 15 mg and another three patients with 20 mg. The percentage of patients with doses ≤ 5 mg was similar in Asian countries and in non-Asian countries (77% and 76% respectively).
Thirteen reports (14%) were classed as serious, two of them were fatal, and 18 (19%) were classed as non-serious. In the two fatal cases, other BGLDs were suspected (ipragliflozin and sitagliptin); glibenclamide is reported as not withdrawn. Two ICSRs reported syncope as an adverse reaction, which indicates a more serious state. Alternative causes of hypoglycaemia
Possible interactions: An ICSR from a non-Asian country reports hypoglycaemia in a 78-year-old woman treated with hydroxychloroquine because of a rheumatoid arthritis. Three Asian country reports mention drugs possibly interacting: one of a 75- year-old woman, who started a triple therapy with metformin 1 g, pioglitazone 30 mg and glibenclamide 5 mg, and presented with palpitations and dizziness on the seventh day; another one mentions phenytoin administration with confusing TTO dates; another report mentions hypoglycaemic symptoms the same day that amoxicillin was administered, and 10 days after the therapy with glibenclamide was started.
Changes in physical activity: An ICSR from a non-Asian country reports the case of a 62-year-old woman under therapy with glibenclamide and metformin who developed bouts of palpitations, confusion, and chest discomfort, particularly at times of unpredicted physical activity.
Incident comorbidities and incident concomitant therapies: An ICSR from an Asian country reports hypoglycaemia in a 52-year-old woman who was started on dual therapy with metformin 1 g daily and glibenclamide 5 mg; the TTO was 10 days. On day 8, a prescription of 2 g of amoxicillin is reported (only one-day of treatment), and doxycycline 200 mg daily, given for three days, because of an acute upper respiratory infection.
Some anti-infective agents may enhance the hypoglycaemic effect of glibenclamide and infection itself can trigger hypoglycaemia.
An ICSR from a non-Asian country reports hypoglycaemia and palpitations in a 59-year-old woman treated with glibenclamide 5 mg over nine months. Two days before the hypoglycaemic event occurred, the patient had received medication for a cardiac event (morphine, nifedipine, isosorbide dinitrate, furosemide, enalapril).
Other alternative causes: In two reports from a non-Asian country (TTO 170 days and 215 days), palpitations are more likely related with other morbidities (atrial fibrillation, reduced left ventricular ejection fraction). In another ICSR from an Asian country (TTO 270 days), other medications suggesting an acute coronary syndrome are reported.""" ;
                     rdfs:label "Reports in Vigibase" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlSUs_Metabolism_and_isoenzymes_genetic_polymorphisms
:SUs_Metabolism_and_isoenzymes_genetic_polymorphisms rdf:type owl:NamedIndividual ,
                                                              <http://purl.obolibrary.org/obo/OAE_0001197> ;
                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hypoglycemia ;
                                                     mp:references :Ref.17 ,
                                                                   :Ref.18 ,
                                                                   :Ref.19 ,
                                                                   :Ref.20 ,
                                                                   :Ref.21 ,
                                                                   :Ref.22 ;
                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """SUs Metabolism and isoenzymes genetic polymorphisms
A PK study performed in healthy male volunteers showed that in homozygous carriers of the genotype *3/*3, total oral clearance was less than half of that of the wildtype genotype *1/*1 (P
<.001). Correspondingly, insulin secretion measured within 12 hours after glyburide ingestion was higher in carriers of the genotype *3/*3 compared with the other genotypes (P =.028), with no clinical effects.17
In a case-control study of 20 diabetic patients admitted to the emergency department with severe hypoglycaemia during SU drug treatment, it was found that the CYP2C9 genotypes *3/*3 and *2/*3 that are predictive of low enzyme activity were more common in the hypoglycaemic group than in the comparison groups (10% vs < 2%, respectively). Other factors in the group with severe hypoglycaemia were lower body mass indexes, higher rates of renal failure, older age, and higher doses of glibenclamide.18
In a study assessing the frequency of CYP2C9 genetic variants in Type 2 diabetes mellitus (T2DM) patients receiving sulfonylureas (92 reporting drug- associated hypoglycaemia, and 84 having never experienced hypoglycaemia), it was found that the presence of the allele CYP2C9*3 increased the risk of hypoglycaemia (OR: 1.687, adjusted for age, BMI, mean daily dose of SU, duration of T2DM and renal function; p = 0.011).19
A study performed in Chinese healthy male volunteers found that CYP2C9 polymorphism appears to exert a dominant influence on glibenclamide pharmacokinetics and pharmacodynamics in vivo; hypoglycaemia developed in 3 of 6 CYP2C9*1/*3 carriers and 2 of 12 CYP2C9*1/*1 carriers.20 A prospective population-based study did not observe over-representation of the CYP2C9 slow metabolizer genotypes in the hypoglycaemic patients group. However, in the control group, patients with CYP2C9 genotypes predicting slower metabolism of SU drugs were treated with significantly lower doses than were extensive metabolizers.21
A study performed in Turkey with 108 diabetic patients treated for ≥ 3 months with SUs (glimepiride, gliclazide, glipizide) found that heterozygosity and homozygosity for CYP2C9 variant alleles (*2 or *3) tended to be more frequent among patients who reported hypoglycaemic attacks.22""" ;
                                                     rdfs:label "SUs Metabolism and isoenzymes genetic polymorphisms" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlSitagliptin
:Sitagliptin rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A10BD07" ,
                                                                          "A10BD12" ,
                                                                          "A10BH01" ,
                                                                          "A10BH51" ;
             rdfs:label "Sitagliptin" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlSyncope
:Syncope rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R55" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10042772 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Syncope" ;
         rdfs:label "Syncope" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlTTO0To10Days
:TTO0To10Days rdf:type owl:NamedIndividual ,
                       time:DurationDescription ;
              time:nominalPosition "days" ;
              time:numericDuration 10 ;
              time:numericPosition 0 ;
              rdfs:label "TTO 0 to 10 days" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlTTO12To28Days
:TTO12To28Days rdf:type owl:NamedIndividual ,
                        time:DurationDescription ;
               time:nominalPosition "days" ;
               time:numericDuration 16 ;
               time:numericPosition 12 ;
               rdfs:label "TTO 12 to 28 days" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlTTO1To20Years
:TTO1To20Years rdf:type owl:NamedIndividual ,
                        time:DurationDescription ;
               time:nominalPosition "years" ;
               time:numericDuration 19 ;
               time:numericPosition 1 ;
               rdfs:label "TTO 1 to 20 years" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlTTO33To36Days
:TTO33To36Days rdf:type owl:NamedIndividual ,
                        time:DurationDescription ;
               time:nominalPosition "days" ;
               time:numericDuration 3 ;
               time:numericPosition 33 ;
               rdfs:label "TTO 33 to 36 days" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlTTO43To61Days
:TTO43To61Days rdf:type owl:NamedIndividual ,
                        time:DurationDescription ;
               time:nominalPosition "days" ;
               time:numericDuration 18 ;
               time:numericPosition 43 ;
               rdfs:label "TTO 43 to 61 days" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlTTO90To270Days
:TTO90To270Days rdf:type owl:NamedIndividual ,
                         time:DurationDescription ;
                time:nominalPosition "days" ;
                time:numericDuration 180 ;
                time:numericPosition 90 ;
                rdfs:label "TTO 90 to 270 days" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlTTOWithinAMonth
:TTOWithinAMonth rdf:type owl:NamedIndividual ,
                          time:DurationDescription ;
                 time:nominalPosition "months" ;
                 time:numericDuration 1 ;
                 time:numericPosition 0 ;
                 rdfs:label "TTO Within a month" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlTotalReportswithTTO0To10Days
:TotalReportswithTTO0To10Days rdf:type owl:NamedIndividual ,
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TTO0To10Days ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 30 ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                              rdfs:label "Total Reports withTTO 0 to 10 days" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlTotalReportswithTTO12To28Days
:TotalReportswithTTO12To28Days rdf:type owl:NamedIndividual ,
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TTO12To28Days ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 4 ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                               rdfs:label "Total Reports withTTO 12 to 28 days" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlTotalReportswithTTO1To20Years
:TotalReportswithTTO1To20Years rdf:type owl:NamedIndividual ,
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TTO1To20Years ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 7 ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                               rdfs:label "Total Reports withTTO 1 to 20 years" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlTotalReportswithTTO33To36Days
:TotalReportswithTTO33To36Days rdf:type owl:NamedIndividual ,
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TTO33To36Days ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                               rdfs:label "Total Reports withTTO 33 to 36 days" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlTotalReportswithTTO43To61Days
:TotalReportswithTTO43To61Days rdf:type owl:NamedIndividual ,
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TTO43To61Days ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 3 ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                               rdfs:label "Total Reports withTTO 43 to 61 days" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlTotalReportswithTTO90To270Days
:TotalReportswithTTO90To270Days rdf:type owl:NamedIndividual ,
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TTO90To270Days ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 9 ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                rdfs:label "Total Reports withTTO 90 to 270 days" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlTotalReportswithTTOWithinAMonth
:TotalReportswithTTOWithinAMonth rdf:type owl:NamedIndividual ,
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TTOWithinAMonth ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 4 ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                 rdfs:label "Total Reports withTTO Within a month" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlType2DiabetesMellitus
:Type2DiabetesMellitus rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "E119" ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10067585 ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Type 2 diabetes mellitus" ;
                       rdfs:label "Type 2 diabetes mellitus" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlUS_FDA_label
:US_FDA_label rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Structured_Product_Labels_information> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :glibenclamide ;
              mp:references :Ref.4 ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """The US FDA label only mentions CYP2C9 as induced 
by rifampicin, and potentially reducing 
glibenclamide plasma levels as a consequence. 
There is no mention of poor metabolizers.4""" ;
              rdfs:label "US FDA label" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlUsage_of_glibenclamide
:Usage_of_glibenclamide rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :Type2DiabetesMellitus ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_related_with_drug_intake> :oral_intake_for_glibenclamide ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :DefinedDailyDoseNonvmicronized ,
                                                                                         :DefinedDailyDoseToMicronized ,
                                                                                         :dailyDoseOfGlibenclamide ,
                                                                                         :startingDoseOfGlibenclamide ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :glibenclamide ;
                        mp:references :Ref.4 ,
                                      :Ref.5 ;
                        rdfs:label "Usage of glibenclamide" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlcancerRenal
:cancerRenal rdf:type owl:NamedIndividual ,
                      <http://purl.obolibrary.org/obo/OAE_0000121> ;
             <http://purl.obolibrary.org/obo/RO_0002170> :Hypoglycemia ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "C64.9" ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10038389 ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Renal cancer" ;
             rdfs:label "cancer renal" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlcardiovascularDisease
:cardiovascularDisease rdf:type owl:NamedIndividual ,
                                <http://purl.obolibrary.org/obo/OAE_0000121> ;
                       <http://purl.obolibrary.org/obo/RO_0002170> :Hypoglycemia ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I51. 9" ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10007541 ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Cardiac disorders" ;
                       rdfs:label "cardiovascular disease" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owldailyDoseOfGlibenclamide
:dailyDoseOfGlibenclamide rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :glibenclamide ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :one_day_interval_during_administration ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg" ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 1.25 ,
                                                                                    20 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "1.25 mg" ,
                                                                                               "20 mg" ;
                          rdfs:label "daily dose of glibenclamide" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlgefitinib_EMA_label
:gefitinib_EMA_label rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Structured_Product_Labels_information> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Gefitinib ;
                     mp:references :Ref.16 ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "According to a paper published in 2014, gefitinib product information is the only EMA label containing a warning about CYP2C9 metabolization.16" ;
                     rdfs:label "gefitinib EMA label" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlglibenclamide
:glibenclamide rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#hasClass> :sulfonylureas ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_mechanism> :glibenclamide_and_CYP2C_isoenzyme ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A10BB01" ;
               rdfs:label "glibenclamide" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlglibenclamide_and_CYP2C_isoenzyme
:glibenclamide_and_CYP2C_isoenzyme rdf:type owl:NamedIndividual ,
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Mechanism> ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Glibenclamide is metabolized by CYP2C9 isoenzyme, which is highly polymorphic. The frequency of polymorphism of defective CYP2C9 alleles (CYP2C9*2 and CYP2C9*3 variants) in South-Asian populations is reported to be 10-25% of a total population; defective isoforms are also present – but much less frequently - in Caucasian populations. Poor metabolizers (CYP2C9*2 and CYP2C9*3 alleles carriers) can show higher plasmatic levels of glibenclamide, leading to low blood glucose levels and triggering counter regulation mechanisms, such as adrenergic response." ;
                                   rdfs:label "glibenclamide and CYP2C isoenzyme" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlglibenclamide_and_higher_risk_of_hypoglycaemia
:glibenclamide_and_higher_risk_of_hypoglycaemia rdf:type owl:NamedIndividual ,
                                                         <http://purl.obolibrary.org/obo/OAE_0001197> ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hypoglycemia ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :glibenclamide ;
                                                mp:references :Ref.10 ,
                                                              :Ref.6 ,
                                                              :Ref.7 ,
                                                              :Ref.8 ,
                                                              :Ref.9 ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Several studies which evaluated the safety of SUs consistently showed that glibenclamide is associated with a higher risk of hypoglycaemia when compared to other SUs, including glipizide, gliclazide and glimepiride.6-9 Glibenclamide was associated with a 52% greater risk of experiencing at least one episode of hypoglycaemia compared with other secretagogues (relative risk 1.52 [95% CI 1.21-1.92]) and with an 83% greater risk compared with other sulfonylureas (1.83 [1.35- 2.49]).10" ;
                                                rdfs:label "glibenclamide and higher risk of hypoglycaemia" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlhepaticDisease
:hepaticDisease rdf:type owl:NamedIndividual ,
                         <http://purl.obolibrary.org/obo/OAE_0000121> ;
                <http://purl.obolibrary.org/obo/RO_0002170> :Hypoglycemia ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "K76. 9" ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10000804 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Acute hepatic failure" ;
                rdfs:label "hepatic disease" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlincidence_of_cyp2c9__allele_2_in_Europeans
:incidence_of_cyp2c9__allele_2_in_Europeans rdf:type owl:NamedIndividual ,
                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Statistical_Entity> ;
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 0.117 ;
                                            rdfs:label "incidence of cyp2c9  allele 2 in Europeans" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlincidence_of_cyp2c9__allele_2_in_admixed_Americans
:incidence_of_cyp2c9__allele_2_in_admixed_Americans rdf:type owl:NamedIndividual ,
                                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Statistical_Entity> ;
                                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 0.06 ;
                                                    rdfs:label "incidence of cyp2c9  allele 2 in admixed Americans" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlincidence_of_cyp2c9__allele_3_in_East_Asians
:incidence_of_cyp2c9__allele_3_in_East_Asians rdf:type owl:NamedIndividual ,
                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Statistical_Entity> ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 0.034 ;
                                              rdfs:label "incidence of cyp2c9  allele 3 in East Asians" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlinfection
:infection rdf:type owl:NamedIndividual ,
                    <http://purl.obolibrary.org/obo/OAE_0000121> ;
           <http://purl.obolibrary.org/obo/RO_0002170> :Hypoglycemia ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "A49.9" ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10021789 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Infection" ;
           rdfs:label "infection" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlintroduction
:introduction rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Introduction> ;
              mp:references :Ref.1 ,
                            :Ref.10 ,
                            :Ref.11 ,
                            :Ref.12 ,
                            :Ref.13 ,
                            :Ref.2 ,
                            :Ref.3 ,
                            :Ref.4 ,
                            :Ref.5 ,
                            :Ref.6 ,
                            :Ref.7 ,
                            :Ref.8 ,
                            :Ref.9 ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Introduction
Glibenclamide is an oral blood glucose lowering drug (BGLD), a second-generation sulfonylurea (SU). SUs induce glucose-independent insulin release from the pancreatic β-cells by binding to the ATP-sensitive potassium (KATP) channel. The polymorphic enzyme cytochrome P450 (CYP) 2C9 is the main enzyme catalysing the biotransformation of SUs.
Hypoglycaemia is a pharmacological, dose- dependent (type A) adverse effect of blood glucose lowering agents, especially insulin and insulin secretagogues. Mild hypoglycaemia is associated with adrenergic and neurogenic symptoms, such as tremor, palpitations and perspiration. Severe hypoglycaemia is characterized by symptoms related to reduced glucose to the brain, such as weakness, poor concentration, slurred speech, confusion or even seizure or coma.
In normal individuals, hypoglycaemic counter regulation is a multifactorial process that involves reduction of insulin secretion, increasing glucagon secretion, adrenergic activation, increased growth hormone and cortisol secretion. Hypoglycaemia increases plasma levels of both epinephrine and norepinephrine, released primarily from the adrenal medulla. Recovery from hypoglycaemia is dependent on the adrenergic response. Individuals with preserved autonomic neurological response manifest these higher levels of catecholamines through palpitations, increased heart rate, piloerection, etc.1
A number of factors can increase the possibility of hypoglycaemic events: over-prescribing, inappropriate dosing, changes in exercise or diet, pharmacodynamic (PD) interactions (other blood glucose lowering agents),2 pharmacokinetic (PK) interactions (agents with high protein-binding), antibiotics, substandard or fake medicines, comorbidities (infection, pancreatic cancer, cancer, renal, hepatic and cardiovascular disease) and patient characteristics (elderly, BMI, poor nutrition).2,3 In addition, published case reports and case series have highlighted the association between CYP2C9 genetic polymorphisms and hypoglycaemic events.
Glibenclamide’s daily dosage is between 1.25 and 20 mg. The usual starting dose of glibenclamide tablets is 2.5 to 5 mg daily.4 The defined daily dose (DDD) is 7 mg or 10 mg (micronized and non- micronized, respectively).5 Glibenclamide is not recommended in the elderly or in individuals with a glomerular filtration rate (GFR)<50 mL/min. The combination of glibenclamide and metformin may have a synergistic effect, since both agents act to improve glucose tolerance by different, but complementary mechanisms.4
Several studies which evaluated the safety of SUs consistently showed that glibenclamide is associated with a higher risk of hypoglycaemia when compared to other SUs, including glipizide, gliclazide and glimepiride.6-9 Glibenclamide was associated with a 52% greater risk of experiencing at least one episode of hypoglycaemia compared with other secretagogues (relative risk 1.52 [95% CI 1.21-1.92]) and with an 83% greater risk compared with other sulfonylureas (1.83 [1.35-
2.49]).10
According to the National List of Essential Medicines (NLEMs), glibenclamide (2.5 and 5.0 mg) is an essential SU in five countries, India, Pakistan, Nepal, Sri Lanka and Bangladesh. In Sri Lanka, glibenclamide is the most commonly prescribed SU by GPs.11
The polymorphic CYP2C9 isoenzyme catalyses the biotransformation of SUs in the liver. The mutant alleles CYP2C9*2 and CYP2C9*3 are known to have a reduced drug-metabolizing activity than the wildtype CYP2C9*1, the decrease in catalysing activity of the *3 allele being more pronounced. The
*3 variant is most common in Asians with a frequency of 10%–25% compared to that of 2%– 6% in Caucasians. Involvement of CYP2C19 in the metabolism of SUs is also reported. CYP2C19*2 and CYP2C19*3 are variants that encode a non- functional CYP2C19 enzyme. Individuals with either of the variants are labelled as poor metabolizers.12
In Asian populations, genetic variability of CYP2C9 is dominated by the less functioning allele *3 (3.4% in East Asians and 11.3% in South Asians) while in Europeans, genetic variability expresses mainly the
*2 variant (Europeans 11.7% and admixed Americans 6.6%), Other allelic variants are also present in South Asian and African populations. 13""" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlipragliflozin
:ipragliflozin rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A10BK05" ;
               rdfs:label "ipragliflozin" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlnonToAsianReports24To44Years
:nonToAsianReports24To44Years rdf:type owl:NamedIndividual ,
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsFromNonToAsianCountries ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 0 ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_max_age> 44 ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 24 ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                              rdfs:label "non to Asian reports 24 to 44 years" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlnonToAsianReports45To64Years
:nonToAsianReports45To64Years rdf:type owl:NamedIndividual ,
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsFromNonToAsianCountries ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 22 ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_max_age> 64 ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 45 ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                              rdfs:label "non to Asian reports 45 to 64 years" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlnonToAsianReports65To74Years
:nonToAsianReports65To74Years rdf:type owl:NamedIndividual ,
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsFromNonToAsianCountries ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 7 ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_max_age> 74 ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 65 ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                              rdfs:label "non to Asian reports 65 to 74 years" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlnonToAsianReports6Years
:nonToAsianReports6Years rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsFromNonToAsianCountries ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 6 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                         rdfs:label "non to Asian reports 6 years" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlnonToAsianReportsAbove75Years
:nonToAsianReportsAbove75Years rdf:type owl:NamedIndividual ,
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsFromNonToAsianCountries ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 9 ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 75 ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                               rdfs:label "non to Asian reports above 75 years" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlnonToAsianReportsTotalAbove65Years
:nonToAsianReportsTotalAbove65Years rdf:type owl:NamedIndividual ,
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsFromNonToAsianCountries ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 16 ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 65 ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                    rdfs:label "non to Asian reports Total above 65 years" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlnonToAsianReportsTotalBelow64Years
:nonToAsianReportsTotalBelow64Years rdf:type owl:NamedIndividual ,
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsFromNonToAsianCountries ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 23 ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_max_age> "64.0"^^xsd:float ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                    rdfs:label "non to Asian reports Total below 64 years" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlone_day_interval_during_administration
:one_day_interval_during_administration rdf:type owl:NamedIndividual ,
                                                 time:DurationDescription ;
                                        time:nominalPosition "days" ;
                                        time:numericPosition 1 ;
                                        rdfs:label "one day interval during administration" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owloral_intake_for_glibenclamide
:oral_intake_for_glibenclamide rdf:type owl:NamedIndividual ,
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Intake_Form> ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :glibenclamide ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_form_of_intake> "oral" ;
                               rdfs:label "oral intake for glibenclamide" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlpancreaticCancer
:pancreaticCancer rdf:type owl:NamedIndividual ,
                           <http://purl.obolibrary.org/obo/OAE_0000121> ;
                  <http://purl.obolibrary.org/obo/RO_0002170> :Hypoglycemia ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "C25.9" ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10033575 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Pancreas cancer" ;
                  rdfs:label "pancreatic cancer" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlpvSignal
:pvSignal rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Signal> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> :Discussion_and_Conclusion ,
                                                                                      :Pathophysiology_of_hypoglycaemia ,
                                                                                      :Polymorphic_CYP2C9 ,
                                                                                      :Prescription_of_glibenclamide ,
                                                                                      :Reports_in_Vigibase ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_supported_by_statistical_entity> :AsianReports24To44Years ,
                                                                                             :AsianReports45To64Years ,
                                                                                             :AsianReports65To74Years ,
                                                                                             :AsianReports6Years ,
                                                                                             :AsianReportsAbove75Years ,
                                                                                             :AsianReportsTotalAbove65Years ,
                                                                                             :AsianReportsTotalBelow64Years ,
                                                                                             :ReportsFromGermany ,
                                                                                             :ReportsFromIndia ,
                                                                                             :ReportsFromJapan ,
                                                                                             :ReportsFromPeru ,
                                                                                             :ReportsFromSingapore ,
                                                                                             :ReportsFromSweden ,
                                                                                             :ReportsFromThailand ,
                                                                                             :ReportsFromUS ,
                                                                                             :ReportsWithAsianTTO0To10Days ,
                                                                                             :ReportsWithAsianTTO12To28Days ,
                                                                                             :ReportsWithAsianTTO1To20Years ,
                                                                                             :ReportsWithAsianTTO33To36Days ,
                                                                                             :ReportsWithAsianTTO43To61Days ,
                                                                                             :ReportsWithAsianTTO90To270Days ,
                                                                                             :ReportsWithAsianTTOWithinAMonth ,
                                                                                             :Reports_from_Denmark ,
                                                                                             :Reports_from_Eritrea ,
                                                                                             :Reports_from_Italy ,
                                                                                             :Reports_from_Malaysia ,
                                                                                             :Reports_from_Namibia ,
                                                                                             :Reports_from_Oman ,
                                                                                             :Reports_from_Spain ,
                                                                                             :Reports_from_UK ,
                                                                                             :TotalReportswithTTO0To10Days ,
                                                                                             :TotalReportswithTTO12To28Days ,
                                                                                             :TotalReportswithTTO1To20Years ,
                                                                                             :TotalReportswithTTO33To36Days ,
                                                                                             :TotalReportswithTTO43To61Days ,
                                                                                             :TotalReportswithTTO90To270Days ,
                                                                                             :TotalReportswithTTOWithinAMonth ,
                                                                                             :incidence_of_cyp2c9__allele_2_in_Europeans ,
                                                                                             :incidence_of_cyp2c9__allele_2_in_admixed_Americans ,
                                                                                             :incidence_of_cyp2c9__allele_3_in_East_Asians ,
                                                                                             :nonToAsianReports24To44Years ,
                                                                                             :nonToAsianReports45To64Years ,
                                                                                             :nonToAsianReports65To74Years ,
                                                                                             :nonToAsianReports6Years ,
                                                                                             :nonToAsianReportsAbove75Years ,
                                                                                             :nonToAsianReportsTotalAbove65Years ,
                                                                                             :nonToAsianReportsTotalBelow64Years ,
                                                                                             :reportsFromAsiaWithPharmacistAsAReporter ,
                                                                                             :reportsFromAsiaWithPhysicianAsAReporter ,
                                                                                             :reportsFromNonToAsianCountries ,
                                                                                             :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ,
                                                                                             :reportsWith10Mg ,
                                                                                             :reportsWith15Mg ,
                                                                                             :reportsWith20Mg ,
                                                                                             :reportsWith5Mg ,
                                                                                             :reportsWithFatalOutcome ,
                                                                                             :reportsWithHypoclycaemiaAsASymptom ,
                                                                                             :reportsWithOnsetData ,
                                                                                             :reportsWithOnsetDateBeforeGlibenclamideAdministration ,
                                                                                             :reportsWithSeriousOutcome ,
                                                                                             :reportsWithSyncopeAsAE ,
                                                                                             :reports_from_asian_countries ,
                                                                                             :totalReports24To44Years ,
                                                                                             :totalReports45To64Years ,
                                                                                             :totalReports65To74Years ,
                                                                                             :totalReports6Years ,
                                                                                             :totalReportsAbove75Years ,
                                                                                             :totalReportsTotalAbove65Years ,
                                                                                             :totalReportsTotalBelow64Years ,
                                                                                             <http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#ReportsFromAustralia,Italy,Denmark,Eritrea,Namibia,Oman,SpainAndUnitedKingdom> ,
                                                                                             <http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#ReportsFromCanada,> ,
                                                                                             <http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#ReportsFromChina,Malaysia> ,
                                                                                             <http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#incidence_of_cyp2c9__allele_*3_in_South_Asians> ,
                                                                                             <http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#reports0,10,28> ,
                                                                                             <http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#reports0,310,69> ,
                                                                                             <http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#reports0,70> ,
                                                                                             <http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#reportsFromAsiaWithACompletenessScoreAbove0,50> ,
                                                                                             <http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#reportsWith1,8Mg> ,
                                                                                             <http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#reportsWith2To2,5Mg> ,
                                                                                             <http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#reportsWith3,5Mg> ,
                                                                                             <http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#reportsWith7,5Mg> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Palpitations ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :glibenclamide ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :glibenclamide ;
          mp:supportedByData :Changes_in_physical_activity ,
                             :Incident_comorbidities_and_incident_concomitant_therapies ,
                             :Incident_comorbidities_and_incident_concomitant_therapies_2 ,
                             :Possible_drug_drug_interactions_2 ,
                             :Possible_interactions ,
                             :SUs_Metabolism_and_isoenzymes_genetic_polymorphisms ,
                             :US_FDA_label ,
                             :gefitinib_EMA_label ,
                             :glibenclamide_and_higher_risk_of_hypoglycaemia ;
          rdfs:label "pv signal" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlreportsFromAsiaWithPharmacistAsAReporter
:reportsFromAsiaWithPharmacistAsAReporter rdf:type owl:NamedIndividual ,
                                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reports_from_asian_countries ;
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_reporter_type> "pharmacist" ;
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                          rdfs:label "reports from asia with pharmacist as a reporter" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlreportsFromAsiaWithPhysicianAsAReporter
:reportsFromAsiaWithPhysicianAsAReporter rdf:type owl:NamedIndividual ,
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reports_from_asian_countries ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 34 ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_reporter_type> "physician" ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                         rdfs:label "reports from asia with physician as a reporter" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlreportsFromNonToAsianCountries
:reportsFromNonToAsianCountries rdf:type owl:NamedIndividual ,
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 48 ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                rdfs:label "reports from non asian countries" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlreportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval
:reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval rdf:type owl:NamedIndividual ,
                                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Palpitations ;
                                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :glibenclamide ;
                                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 95 ;
                                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count_of_men> 30 ;
                                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count_of_women> 60 ;
                                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                            rdfs:label "overall reports of glibenclamide and palpitations after duplicate removal" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlreportsWith10Mg
:reportsWith10Mg rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :GlibenclamideDosage10Mg ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 9 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                 rdfs:label "reports with 10 mg" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlreportsWith15Mg
:reportsWith15Mg rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :GlibenclamideDosage15Mg ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 3 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                 rdfs:label "reports with 15 mg" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlreportsWith20Mg
:reportsWith20Mg rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :GlibenclamideDosage20Mg ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 3 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                 rdfs:label "reports with 20 mg" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlreportsWith5Mg
:reportsWith5Mg rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :GlibenclamideDosage5Mg ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 33 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                rdfs:label "reports with 5 mg" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlreportsWithFatalOutcome
:reportsWithFatalOutcome rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsWithSeriousOutcome ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Sitagliptin ,
                                                                                                          :ipragliflozin ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "death" ;
                         rdfs:label "reports with fatal outcome" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlreportsWithHypoclycaemiaAsASymptom
:reportsWithHypoclycaemiaAsASymptom rdf:type owl:NamedIndividual ,
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hypoglycemia ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 18 ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                    rdfs:label "reports with hypoclycaemia as a symptom" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlreportsWithOnsetData
:reportsWithOnsetData rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Onset date and at least start date of glibenclamide therapy were stated in 59 out of 95 ICSRs (57.9%); so it was possible to calculate time-to-onset (TTO) in this subset of reports." ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 59 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                      rdfs:label "reports with onset data" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlreportsWithOnsetDateBeforeGlibenclamideAdministration
:reportsWithOnsetDateBeforeGlibenclamideAdministration rdf:type owl:NamedIndividual ,
                                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "In three ICSRs, the onset date was stated as previous to the reported start of drug administration." ;
                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 3 ;
                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                       rdfs:label "reports with onset date before glibenclamide administration" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlreportsWithSeriousOutcome
:reportsWithSeriousOutcome rdf:type owl:NamedIndividual ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 13 ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                           rdfs:label "reports with serious outcome" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlreportsWithSyncopeAsAE
:reportsWithSyncopeAsAE rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Syncope ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                        rdfs:label "reports with syncope as AE" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlreports_from_asian_countries
:reports_from_asian_countries rdf:type owl:NamedIndividual ,
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 47 ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                              rdfs:label "reports from asian countries" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlstartingDoseOfGlibenclamide
:startingDoseOfGlibenclamide rdf:type owl:NamedIndividual ,
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :glibenclamide ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_interval_between_administrations> :one_day_interval_during_administration ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg" ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 2.5 ,
                                                                                       5 ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "2.5 mg" ,
                                                                                                  "5 mg" ;
                             rdfs:label "starting dose of glibenclamide" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlsulfonylureas
:sulfonylureas rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#DrugClass> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_mechanism> :Mechanism_of_Glibenclamide ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A10BB" ;
               rdfs:label "sulfonylureas" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owlsummary
:summary rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Summary> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Glibenclamide (glyburide in the US) is an oral blood glucose lowering drug (BGLD), a second-generation, long-acting sulfonylurea (SU) approved for use in the US in 1984, following its introduction in Europe by several years; in other countries it was approved later (in Singapore in 1990). SUs are currently first- line agents or an add-on therapy to other oral hypoglycaemic agents (OHAs), usually metformin. About a quarter of newly-diagnosed patients initiate therapy with SUs.
Sulfonylureas stimulate insulin release by binding to specific sites on the beta cells (insulin secretagogue agent). As other SUs, glibenclamide is metabolized in the liver and excreted by the kidney. The genetically polymorphic cytochrome P450 (CYP), enzyme CYP2C9 is mainly responsible for the hepatic metabolism of sulfonylureas (SUs). It has been found that pharmacokinetics of glibenclamide depends significantly on CYP2C9 genotypes.
CYP2C9 pharmacogenetic variants are more frequent in South-Asian populations (10-25%) than in Caucasian ones (2%–6%).
Hypoglycaemia, a very well-known type A adverse effect of glibenclamide and other BGLDs, can manifest through a variety of symptoms.
Palpitations are an unspecific symptom that can be the expression of the adrenergic counter-regulation to hypoglycaemia.
One hundred individual case safety reports (ICSRs) with the combination glibenclamide and palpitations were retrieved from VigiBase, the WHO global database of ICSRs on 15 January 2018. Many also mention other related terms, including hypoglycaemia, sweating and blurred vision. Half of the set came from South-Asian countries. In the 59 reports in which time to onset (TTO) could be calculated, it ranged from 0 days to 20 years, with the majority (30 reports) in the 0 to 10 days group. Of these 30 reports, 21 originated from South-Asian countries.
To the best of our knowledge, for glibenclamide there is no regulatory labelling or warning that refers to an increased risk of hypoglycaemia in patients with defective isoenzyme genetics.
ICSRs contain limited information, and a patient’s pharmacogenetic status is usually never stated. In spite of these known limitations, we have identified characteristics of ICSRs mentioning glibenclamide as a suspected drug, and palpitations as an early hypoglycaemic symptom that could be suggestive of a defective metabolism (short time-to-onset, geographic region). We hypothesize that patients presenting with hypoglycaemia and with a short TTO could have defective genetic variants, and therefore this is considered a signal.""" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owltotalReports24To44Years
:totalReports24To44Years rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 11 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_max_age> 44 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 24 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                         rdfs:label "total reports 24 to 44 years" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owltotalReports45To64Years
:totalReports45To64Years rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 47 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_max_age> 64 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 45 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                         rdfs:label "total reports 45 to 64 years" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owltotalReports65To74Years
:totalReports65To74Years rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 13 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_max_age> 74 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 65 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                         rdfs:label "total reports 65 to 74 years" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owltotalReports6Years
:totalReports6Years rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 6 ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                    rdfs:label "total reports 6 years" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owltotalReportsAbove75Years
:totalReportsAbove75Years rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 14 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 75 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                          rdfs:label "total reports above 75 years" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owltotalReportsTotalAbove65Years
:totalReportsTotalAbove65Years rdf:type owl:NamedIndividual ,
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 26 ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 65 ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                               rdfs:label "total reports Total above 65 years" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owltotalReportsTotalBelow64Years
:totalReportsTotalBelow64Years rdf:type owl:NamedIndividual ,
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 61 ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_max_age> "64.0"^^xsd:float ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                               rdfs:label "total reports Total below 64 years" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#Glibenclamide/glyburide_and_palpitations_in_the_Asian_population
<http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#Glibenclamide/glyburide_and_palpitations_in_the_Asian_population> rdf:type owl:NamedIndividual ,
                                                                                                                                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Pharmacovigilance_Signal_Report> ;
                                                                                                                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_author> :Raquel_Herrera_Comoglio ;
                                                                                                                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_signal> :pvSignal ;
                                                                                                                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_creation_date> "01/05/2019"^^xsd:date ;
                                                                                                                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_overall_conclusion> "causal association probable" ;
                                                                                                                                                       rdfs:label "Glibenclamide/glyburide and palpitations in the Asian population" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#GlibenclamideDosage1,8Mg
<http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#GlibenclamideDosage1,8Mg> rdf:type owl:NamedIndividual ,
                                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :glibenclamide ;
                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg" ;
                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 1.8 ;
                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "1.8 mg" ;
                                                                                                               rdfs:label "Glibenclamide Dosage 1,8 mg" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#GlibenclamideDosage3,5Mg
<http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#GlibenclamideDosage3,5Mg> rdf:type owl:NamedIndividual ,
                                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :glibenclamide ;
                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg" ;
                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 3.5 ;
                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "3.5 mg" ;
                                                                                                               rdfs:label "Glibenclamide Dosage 3,5 mg" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#GlibenclamideDosage7,5Mg
<http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#GlibenclamideDosage7,5Mg> rdf:type owl:NamedIndividual ,
                                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :glibenclamide ;
                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_dosage_unit> "mg" ;
                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 7.5 ;
                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "7.5 mg" ;
                                                                                                               rdfs:label "Glibenclamide Dosage 7,5 mg" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#ReportsFromAustralia,Italy,Denmark,Eritrea,Namibia,Oman,SpainAndUnitedKingdom
<http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#ReportsFromAustralia,Italy,Denmark,Eritrea,Namibia,Oman,SpainAndUnitedKingdom> rdf:type owl:NamedIndividual ,
                                                                                                                                                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                                                                                                                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsFromNonToAsianCountries ;
                                                                                                                                                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                                                                                                                                                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Australia" ;
                                                                                                                                                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                                                                                                                                    rdfs:label "Reports from Australia" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#ReportsFromCanada,
<http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#ReportsFromCanada,> rdf:type owl:NamedIndividual ,
                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsFromNonToAsianCountries ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Canada" ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                                                                         rdfs:label "Reports from Canada" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#ReportsFromChina,Malaysia
<http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#ReportsFromChina,Malaysia> rdf:type owl:NamedIndividual ,
                                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                                                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reports_from_asian_countries ;
                                                                                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 3 ;
                                                                                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/China" ;
                                                                                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                                                                                rdfs:label "Reports from China" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#incidence_of_cyp2c9__allele_*3_in_South_Asians
<http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#incidence_of_cyp2c9__allele_*3_in_South_Asians> rdf:type owl:NamedIndividual ,
                                                                                                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Statistical_Entity> ;
                                                                                                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 0.113 ;
                                                                                                                                     rdfs:label "incidence of cyp2c9  allele *3 in South Asians" ,
                                                                                                                                                "incidence of cyp2c9  allele 3 in South Asians" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#reports0,10,28
<http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#reports0,10,28> rdf:type owl:NamedIndividual ,
                                                                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                                                                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 29 ;
                                                                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                                                                     rdfs:label "reports with completeness score 0,1 - 0,28" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#reports0,310,69
<http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#reports0,310,69> rdf:type owl:NamedIndividual ,
                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                                                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                                                                                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 43 ;
                                                                                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                                                                      rdfs:label "reports with completeness score 0,31 - 0,69" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#reports0,70
<http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#reports0,70> rdf:type owl:NamedIndividual ,
                                                                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 23 ;
                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                                                                  rdfs:label "reports with completeness score over 0,70" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#reportsFromAsiaWithACompletenessScoreAbove0,50
<http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#reportsFromAsiaWithACompletenessScoreAbove0,50> rdf:type owl:NamedIndividual ,
                                                                                                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                                                                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reports_from_asian_countries ;
                                                                                                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Most of the Asian ICSRs (34/47, 72%) had a completeness score (level of documentation) >0.50." ;
                                                                                                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 34 ;
                                                                                                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                                                                                                     rdfs:label "reports from Asia with a completeness score above 0,50" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#reportsWith1,8Mg
<http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#reportsWith1,8Mg> rdf:type owl:NamedIndividual ,
                                                                                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                                                                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> <http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#GlibenclamideDosage1,8Mg> ;
                                                                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                                                                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                                                                       rdfs:label "reports with 1,8 mg" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#reportsWith2To2,5Mg
<http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#reportsWith2To2,5Mg> rdf:type owl:NamedIndividual ,
                                                                                                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                                                                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> :GlibenclamideDosage2To2.5Mg ;
                                                                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 13 ;
                                                                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                                                                          rdfs:label "reports with 2 to 2,5 mg " .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#reportsWith3,5Mg
<http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#reportsWith3,5Mg> rdf:type owl:NamedIndividual ,
                                                                                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                                                                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> <http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#GlibenclamideDosage3,5Mg> ;
                                                                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                                                                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                                                                       rdfs:label "reports with 3,5 mg" .


###  http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#reportsWith7,5Mg
<http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#reportsWith7,5Mg> rdf:type owl:NamedIndividual ,
                                                                                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :reportsOfGlibenclamideAndPalpitationsAfterDuplicateRemoval ;
                                                                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dosage> <http://purl.org/OpenPVSignal/Signals/2019_2_glibenclamideglyburide_palpitations.owl#GlibenclamideDosage7,5Mg> ;
                                                                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                                                                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                                                                       rdfs:label "reports with 7,5 mg" .


#################################################################
#    Annotations
#################################################################

:introduction rdfs:label "introduction" .


:summary rdfs:label "summary" .


###  Generated by the OWL API (version 4.5.9.2019-02-01T07:24:44Z) https://github.com/owlcs/owlapi
